Roles for TGF-β and Programmed Cell Death 1 Ligand 1 in Regulatory T Cell Expansion and Diabetes Suppression by Zymosan in Nonobese Diabetic Mice

被引:25
|
作者
Burton, Oliver T. [1 ]
Zaccone, Paola [1 ]
Phillips, Jenny M. [1 ]
De La Pena, Hugo [1 ,2 ]
Fehervari, Zoltan [1 ]
Azuma, Miyuki [3 ]
Gibbs, Sarah [1 ]
Stockinger, Brigitta [2 ]
Cooke, Anne [1 ]
机构
[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
[2] Natl Inst Med Res, MRC, Dept Mol Immunol, London NW7 1AA, England
[3] Tokyo Med & Dent Univ, Dept Mol Immunol, Tokyo, Japan
来源
JOURNAL OF IMMUNOLOGY | 2010年 / 185卷 / 05期
基金
英国惠康基金; 英国生物技术与生命科学研究理事会;
关键词
PLASMACYTOID DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; NOD MICE; EXTRACELLULAR-MATRIX; RECEPTOR DECTIN-1; CANDIDA-ALBICANS; B-LYMPHOCYTES; IN-VIVO; INDUCTION; PREVENTS;
D O I
10.4049/jimmunol.1001365
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Zymosan is a complex fungal component shown to be capable of both promoting and suppressing the development of autoimmune disorders in mice. In this study, we show that a single injection of zymosan just prior to diabetes onset can significantly delay the progression of disease in NOD mice. Zymosan treatment of NOD mice induced the production of biologically active TGF-beta from cells infiltrating the pancreas and was associated with expansion of programmed cell death 1 ligand 1(+)TGF-beta(+) macrophages and Foxp3(+) regulatory T cells in vivo. Neutralization of either TGF-beta or programmed cell death 1 ligand 1 abrogated the protective effects of zymosan. Zymosan acted through TLR2 as well as ERK and p38 MAPK to induce macrophage secretion of TGF-beta and promotion of Foxp3(+) regulatory T cells in vitro and in vivo. The Journal of Immunology, 2010, 185: 2754-2762.
引用
收藏
页码:2754 / 2762
页数:9
相关论文
共 50 条
  • [21] Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications
    Wolkow, Natalie
    Jakobiec, Frederick A.
    Afrogheh, Amir H.
    Eagle, Ralph C., Jr.
    Pai, Sara, I
    Faquin, William C.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 200 : 226 - 241
  • [22] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Deng, Tuo
    Zeng, Guohua
    JAMA ONCOLOGY, 2020, 6 (07) : 1113 - 1114
  • [23] Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
    Fang, Xiao-Na
    Fu, Li-Wu
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2016, 11 (02) : 141 - 151
  • [24] Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma
    Villasboas, Jose Caetano
    Ansell, Stephen
    CANCER JOURNAL, 2016, 22 (01): : 17 - 22
  • [25] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Debasree Banerjee
    Sean Monaghan
    Runping Zhao
    Thomas Walsh
    Amy Palmisciano
    Gary S. Phillips
    Steven Opal
    Mitchell M. Levy
    Critical Care, 22
  • [26] Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
    Banerjee, Debasree
    Monaghan, Sean
    Zhao, Runping
    Walsh, Thomas
    Palmisciano, Amy
    Phillips, Gary S.
    Opal, Steven
    Levy, Mitchell M.
    CRITICAL CARE, 2018, 22
  • [27] Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80
    Haile, Samuel T.
    Bosch, Jacobus J.
    Agu, Nnenna I.
    Zeender, Annette M.
    Somasundaram, Preethi
    Srivastava, Minu K.
    Britting, Sabine
    Wolf, Julie B.
    Ksander, Bruce R.
    Ostrand-Rosenberg, Suzanne
    JOURNAL OF IMMUNOLOGY, 2011, 186 (12): : 6822 - 6829
  • [28] Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
    Qizhi Tang
    Jason Y Adams
    Aaron J Tooley
    Mingying Bi
    Brian T Fife
    Pau Serra
    Pere Santamaria
    Richard M Locksley
    Matthew F Krummel
    Jeffrey A Bluestone
    Nature Immunology, 2006, 7 : 83 - 92
  • [29] Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
    Tang, QZ
    Adams, JY
    Tooley, AJ
    Bi, MY
    Fife, BT
    Serra, P
    Santamaria, P
    Locksley, RM
    Krummel, MF
    Bluestone, JA
    NATURE IMMUNOLOGY, 2006, 7 (01) : 83 - 92
  • [30] Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-β1
    Moritani, M
    Yoshimoto, K
    Wong, SF
    Tanaka, C
    Yamaoka, T
    Sano, T
    Komagata, Y
    Miyazaki, J
    Kikutani, H
    Itakura, M
    JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03): : 499 - 506